# 2026-05527: NIH Licenses Gene-Editing Breakthrough to Cure Rare ROSAH Syndrome Vision Loss

2026-05527, Government-Owned Inventions; Availability for Licensing, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-03-20, effective 2026-03-20; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-05527
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-05527
- Title: Government-Owned Inventions; Availability for Licensing
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 13606
- Published: 2026-03-20
- Effective: 2026-03-20
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

NIH Licenses Gene-Editing Breakthrough to Cure Rare ROSAH Syndrome Vision Loss

## Summary

The National Institutes of Health is offering a cool new gene-editing invention that can fix a rare genetic disease called ROSAH syndrome, which causes vision loss and other problems. Companies can license this technology to develop treatments that might restore vision and improve lives. Interested parties should act soon and be ready to sign a confidentiality agreement to get all the details.

## Abstract

The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

## Effects PRIA read

- Government Gene-Editing Available for Licensing: benefit, medium. The National Institute of Allergy and Infectious Diseases (NIAID) is offering a gene-editing technology that fixes the ALPK1 p.Thr237Met mutation (causing ROSAH syndrome) for licensing to commercial developers under 35 U.S.C. 209 and 37 CFR part 404. Companies interested in commercializing the inve…
- Confidentiality Agreement Needed For Details: cost, low. To receive copies of unpublished information about the invention, interested parties must sign a Confidential Disclosure Agreement (CDA) before NIAID will share full details. Contact David Yang at 240-695-6406 or [email protected] to request information and the CDA.
- Agency Seeking Research Collaborators: benefit, medium. NIAID is seeking statements of capability or interest from parties for collaborative research to further develop, evaluate, or commercialize this technology, with specific interest in human clinical trials. Parties that want to collaborate should contact David Yang at 240-695-6406 or [email protect…
- Patent Filings Extend Market Coverage: benefit, medium. Intellectual property associated with this invention includes Provisional Patent Application No. 63/733,836 filed December 13, 2024, and PCT Patent Application No. PCT/US2025/059432 filed December 12, 2025; foreign patent applications have been filed on selected inventions and may be available for…
- Potential Vision-Restoring Therapy For ROSAH: benefit, high. Researchers report a gene-editing method that precisely repairs the ALPK1 p.Thr237Met mutation in patient-derived cells with high accuracy and no side effects in lab tests, and the therapy could be delivered to the eye or salivary glands or via corrected patient cells returned to the patient. This…
- Technology Is At Pre-Clinical Stage: cost, medium. The notice states the invention's development stage as "Pre-Clinical," indicating it has laboratory results but has not yet entered human clinical trials. NIAID specifically notes interest in collaborators for human clinical trials to advance development.

## Related documents

- [2026-22871](https://policyrisk.com/federal-register/2026-22871): Center for Scientific Review; Notice of Closed Meetings, 2026-11-10
- [2026-22550](https://policyrisk.com/federal-register/2026-22550): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22558](https://policyrisk.com/federal-register/2026-22558): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22339](https://policyrisk.com/federal-register/2026-22339): Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human, 2026-11-02
- [2026-22196](https://policyrisk.com/federal-register/2026-22196): National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting, 2026-10-30
- [2026-22111](https://policyrisk.com/federal-register/2026-22111): Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting, 2026-10-29

## Sources
- [2026-05527 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/20/2026-05527/government-owned-inventions-availability-for-licensing)
- [2026-05527 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-20/pdf/2026-05527.pdf)

## Related
- [Previous: 2026-05526, Center for Scientific Review; Notice of Closed Meetings](https://policyrisk.com/federal-register/2026-05526)
- [Next: 2026-05528, Agency Information Collection Activities; Comment Request; State Workforce Prog…](https://policyrisk.com/federal-register/2026-05528)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-05527 (as of 2026-06-08).
